Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AlpHelix Biosciences specializes in the early discovery of drugs targeting membrane proteins—especially GPCRs—using proprietary technology platforms. The company provides global pharmaceutical partners with services ranging from target preparation and structural determination to hit identification for antibodies, small molecules, and peptides. Their MegaR platform enables efficient production of stable, ligand-free GPCR proteins suitable for high-throughput screening and structure-based drug design. No clinical results are reported as the company operates primarily as a service provider in preclinical research.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AlpHelix Biosciences.